For full functionality of this site it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser.

Once enabled, click here to view the site.

singup link button why should I sign up?
Login as Volunteer Login as Study team member
OR

Studies you may be eligible for. 11

Based on the information you provided, we found the following studies.

  • Ph I Stdy Investigating Safety/Pharmacokinetics/Pharmacodynamics/Immunogenicity/Clinical Activity of GSK2857916 in Subjects with Myeloma/Other Advanced Hematologic Malignancies Exprssng BCMA Study goal: test experimental drug GSK2857916 in patients with multiple myeloma or other blood cancers.Part 1 Dose Escalation: find highest dose that does not cause serious side effects;Part 2 Dose Expansion: test safety, how it behaves in human body, and whether it works in treating your condition. This study is researching all of the following topics: CLL ( Chronic lymphocytic leukemia) Multiple myeloma This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old
  • Phase I Study of an Oncofetal Antigen ("OFA") Multi-Peptide Immunotherapy ("BB-MPI-03"), a vaccine, in Subjects with Hematologic Cancer (BB-MPI-03-Hem-01) Study purpose: determine the highest tolerable dose or optimal biologic dose of peptides in the vaccine that can be given, how it affects your immune system (the system your body uses to fight cancer, infections and ┬┐foreign bodies┬┐) and whether it causes your cancer to shrink or remain stable. This study is researching all of the following topics: AML ( Acute myeloid leukemia ) MDS ( Myelodysplastic syndrome ) Multiple myeloma This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old
  • Phase 2 Multicenter Study of Anti-Programmed-Death-1 [anti-PD-1] during Lymphopenic State After High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplant [HDT/ASCT] for Multiple Myeloma This study will test if additional post-transplant treatment (every 3 weeks for 6 months) with anti-PD1 can lead to a safe and more effective treatment approach for patients with MM, compared with a standard transplant alone. This study is researching all of the following topics: Multiple myeloma This study is looking for: male female both men and women Volunteers with specific conditions
    • Less than 75 years old
    • More than 18 years old
  • Phase 1 Dose Escalation w/Two Disease Specific Expansions, Open-Label, Safety, Pharmacokinetic and Pharmacodynamic Study of APTO-253 in Patients with Relapsed or Refractory Hematologic Malignancies Study Purpose: test the safety of APTO-253; find the maximum dose of APTO-253 which can be tolerated when given two times a week; find out what effects, good and/or bad, this treatment has on you and your cancer and how APTO-253 may work in the body and your body's ability to get rid of APTO-253. This study is researching all of the following topics: ALL ( Acute lymphoblastic leukemia ) AML ( Acute myeloid leukemia ) Hodgkin's lymphoma Leukemia Lymphoma MDS ( Myelodysplastic syndrome ) Multiple myeloma Non-Hodgkin's lymphoma This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old
  • Phase I Study of Experimental Combination of Experimental drug Selinexor with Carfilzomib and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Study goals: find the safest dose and side effects of Selinexor and carfilzomib in combination with dexamethasone in people with multiple myeloma that has not responded to prior treatments, including carfilzomib alone; and learn how well the combination of drugs works against multiple myeloma. This study is researching all of the following topics: Multiple myeloma This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old
  • Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and Graft-versus-host Disease in Allogeneic Hematopoietic Cell Transplantation for High-risk Hematologic Malignancies Investigational drug carfilzomib will be added to a standard chemotherapy conditioning regimen for donor blood stem cell transplant to test if this new conditioning regimen can lead to safe and more effective stem cell transplant treatment approach for patients with quickly worsening blood cancers. This study is researching all of the following topics: ALL ( Acute lymphoblastic leukemia ) AML ( Acute myeloid leukemia ) Amyloidosis CLL ( Chronic lymphocytic leukemia) Leukemia Lymphoma MDS ( Myelodysplastic syndrome ) Multiple myeloma Myelofibrosis Non-Hodgkin's lymphoma This study is looking for: male female both men and women Volunteers with specific conditions
    • Less than 66 years old
    • More than 18 years old
  • Phase 1b/2 Open Label, Dose Escalation Study to Determine Safety & Efficacy of ACY-1215 in Combination with Pomalidomide & Low-dose Dexamethasone in Patients w/ Relapsed & Refractory Multiple Myeloma This part of the study will study will examine how well the drug regimen combination of ACY-1215, when given with pomalidomide and low dose dexamethasone, works, and continue to test the safety of ACY-1215 given at the best dose and schedule, as determined in the first part of this study. This study is researching all of the following topics: Multiple myeloma This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old
  • A Phase 1/2 Dose Escalation Safety, Pharmacokinetic and Efficacy Study of Multiple IV Administrations of SAR650984 Against CD38 In Patients with Selected CD38+ Hematological Malignancies The main purpose of this study is to evaluate the possible risks and the effectiveness of investigational drug SAR650984 in patients with multiple myeloma. This study is researching all of the following topics: ALL ( Acute lymphoblastic leukemia ) AML ( Acute myeloid leukemia ) CLL ( Chronic lymphocytic leukemia) Multiple myeloma Non-Hodgkin's lymphoma This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old
  • Phase 3 Double Blind, Randomized Oral MLN9708/Rev/Dex vs. Placebo/Rev/Dex in Adults with Newly Diagnosed Multiple Myeloma (Protocol C16014) The study purpose is to determine whether adding investigational drug MLN9708 to the combination of lenalidomide and dexamethasone improves survival in patients with newly diagnosed multiple myeloma. This study is researching all of the following topics: Multiple myeloma This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old
  • RVD +/- transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age We are looking to explore the drug combination of lenalidomide, bortezomib, and dexamethasone alone or when combined with autologous stem cell transplantation to see what side effects if may have and how well it works for treatment of newly diagnosed multiple myeloma. This study is researching all of the following topics: Multiple myeloma This study is looking for: male female both men and women Volunteers with specific conditions
    • 18 years to 65 years
Showing 1-10 of 11 studies
Show more studies